Logo Logo
Switch Language to German

Konecny, G. E.; Hendrickson, A. E. Wahner; Davidson, T. M.; Winterhoff, B. J.; Ma, S.; Mahner, S.; Sehouli, J.; Fasching, P. A.; Feisel-Schwickardi, G.; Poelcher, M.; Roman, L. D.; Rody, A.; Karlan, B. Y.; Mullany, S. A.; Chen, H.; Ray-Coquard, I. L.; Provencher, D. M.; Yachnin, A.; Cottu, P. H.; Glaspy, J. A.; Haluska, P. and Slamon, D. J. (2021): Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer. In: Gynecologic Oncology, Vol. 163, No. 3: pp. 465-472

Full text not available from 'Open Access LMU'.


Purpose. Insulin-like growth factor (IGF) signaling is implicated in pathogenesis and chemotherapy resistance of epithelial ovarian cancer (EOC). We explored efficacy and safety of adding ganitumab, a monoclonal antibody targeting IGF-1R, to carboplatin/paclitaxel (CP) chemotherapy in patients with primary EOC. Design. Patients were randomly assigned to receive CP/ganitumab (18 mg/kg q3w) or CP/placebo for 6 cycles followed by 6 cycles of single agent ganitumab/placebo maintenance therapy as front-line therapy. Primary end -point was progression free survival. Secondary endpoints were time to progression and overall survival. Pretreat-ment samples were prospectively collected for retrospective biomarker analyses. Results. 170 patients enrolled. 165 patients assessable for toxicity. Median PFS was 15.7 months with CP/ ganitumab and 16.7 months with CP/placebo (HR 1.23;95% CI 0.82-1.83, P = 0.313). All grade neutropenia (84.1% vs 71.4%), thrombocytopenia (75.3% vs 57.1%) and hyperglycemia (15.9% vs 2.6%) were more common in the ganitumab group compared to the placebo group. Ganitumab/placebo related serious adverse events were reported in 26.1% of the patients with ganitumab and in 6.5% with placebo. Non-progression related fatal events were more common with ganitumab (5 versus 2 patients). The ganitumab group experienced more dose delays which resulted in lower relative dose intensity of chemotherapy in the experimental group. In an exploratory model IGFBP2 expression was predictive of ganitumab response (treatment interaction;PFS, P = 0.03;OS, P = 0.01). Conclusion. Addition of ganitumab to CP chemotherapy in primary EOC did not improve PFS. Our results do not support further study of ganitumab in unselected EOC patients. (c) 2021 The Authors. Published by ELSEVIER. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).

Actions (login required)

View Item View Item